Cat. No：GM-C09467
Product：ADCP FcγRIIa Jurkat Effector Cell Line
Cat. No：GM-C09467
Product：ADCP FcγRIIa Jurkat Effector Cell Line
Cell Growth Medium：RPMI 1640+10% FBS+1% P.S+0.75 μg/mL Puromycin+3.5 μg/mL Blastincidin
Cell Freezing Medium：FBS+10% DMSO
Assay Buffer：99% RPMI 1640+1% low IgG FBS
ADCP, or Antibody-Dependent Cell-Mediated Phagocytosis, refers to the process where immune cells expressing Fc receptors engulf target cells by recognizing the Fc portion of antibodies bound to the specific target. Nowadays, the mechanism of ADCP is used to detect and assess the efficacy of antibodies. When the antibody's Fab portion binds to the target antigen on the cell surface, and the antibody's Fc portion simultaneously binds to the FcγRIIa receptor on effector cells (mainly macrophages), a multiple cross-linking occurs, activating the ADCP pathway, leading to the phagocytosis of target cells. In classic ADCP bioactivity assays, macrophage subpopulations from donors are used as effector cells, which exhibit significant variability, making them difficult to prepare and prone to high background readings.
The ADCP Reporter Gene Assay Kit utilizes engineered Jurkat cells as effector cells, stably expressing human FcγRIIa receptor (131H) and firefly luciferase driven by a transcription factor. The biological activity of antibodies in the ADCP mechanism is quantified by the luciferase produced through NFAT pathway activation, with luciferase activity in effector cells quantified through bioluminescent readings. The detection signals are robust, with low background levels.
With years of research experience, Genomeditech leverages ingenious vector design and third-generation lentiviral reporter gene systems to introduce ADCP-related cell lines and ADCP activity detection services, including customized ADCP cell line services.
| FcγR | ||
| Cynomolgus_FcRn MDCK Cell Line | H_FCGR1A(CD64) CHO-K1 Cell Line | H_FCGR1A(CD64) HEK-293 Cell Line |
| H_FCGR2A(CD32A) CHO-K1 Cell Line | H_FCGR2B(CD32B) CHO-K1 Cell Line | H_FCGR3A(CD16a) 158F CHO-K1 Cell Line |
| H_FCGR3A(CD16a) 158V CHO-K1 Cell Line | H_FCGR3B(CD16b) CHO-K1 Cell Line | H_FcRn CHO-K1 Cell Line |
| H_FcRn MDCK Cell Line | Mouse_FcRn MDCK Cell Line | |
| Anti-FcRn hIgG4 Reference Antibody(Rozabio) | Anti-H_FcRn IgG4 Antibody(Rozanolixizumab) | Anti-Mouse CD1632 mIgG2b Antibody(2.4G2) |
| ADCCP | ||
| ADCC FcγRIIIa(158F) Jurkat Effector Cell Line | ADCC FcγRIIIa(158V) DDX35TM Jurkat Effector Cell Line | ADCC FcγRIIIa(158V) Jurkat Effector Cell Line |
| ADCC M_FcγRIV Jurkat Effector Cell Line | ADCP FcγRI Jurkat Effector Cell Line | ADCP FcγRIIa DDX35TM Jurkat Effector Cell Line |
| ADCP FcγRIIa R131 Jurkat Effector Cell Line | ADCP FcγRIIb Jurkat Effector Cell Line | |
Cat. No：GM-C09467
Product：ADCP FcγRIIa Jurkat Effector Cell Line
Cell Growth Medium：RPMI 1640+10% FBS+1% P.S+0.75 μg/mL Puromycin+3.5 μg/mL Blastincidin
Cell Freezing Medium：FBS+10% DMSO
Assay Buffer：99% RPMI 1640+1% low IgG FBS
ADCP, or Antibody-Dependent Cell-Mediated Phagocytosis, refers to the process where immune cells expressing Fc receptors engulf target cells by recognizing the Fc portion of antibodies bound to the specific target. Nowadays, the mechanism of ADCP is used to detect and assess the efficacy of antibodies. When the antibody's Fab portion binds to the target antigen on the cell surface, and the antibody's Fc portion simultaneously binds to the FcγRIIa receptor on effector cells (mainly macrophages), a multiple cross-linking occurs, activating the ADCP pathway, leading to the phagocytosis of target cells. In classic ADCP bioactivity assays, macrophage subpopulations from donors are used as effector cells, which exhibit significant variability, making them difficult to prepare and prone to high background readings.
The ADCP Reporter Gene Assay Kit utilizes engineered Jurkat cells as effector cells, stably expressing human FcγRIIa receptor (131H) and firefly luciferase driven by a transcription factor. The biological activity of antibodies in the ADCP mechanism is quantified by the luciferase produced through NFAT pathway activation, with luciferase activity in effector cells quantified through bioluminescent readings. The detection signals are robust, with low background levels.
With years of research experience, Genomeditech leverages ingenious vector design and third-generation lentiviral reporter gene systems to introduce ADCP-related cell lines and ADCP activity detection services, including customized ADCP cell line services.
| FcγR | ||
| Cynomolgus_FcRn MDCK Cell Line | H_FCGR1A(CD64) CHO-K1 Cell Line | H_FCGR1A(CD64) HEK-293 Cell Line |
| H_FCGR2A(CD32A) CHO-K1 Cell Line | H_FCGR2B(CD32B) CHO-K1 Cell Line | H_FCGR3A(CD16a) 158F CHO-K1 Cell Line |
| H_FCGR3A(CD16a) 158V CHO-K1 Cell Line | H_FCGR3B(CD16b) CHO-K1 Cell Line | H_FcRn CHO-K1 Cell Line |
| H_FcRn MDCK Cell Line | Mouse_FcRn MDCK Cell Line | |
| Anti-FcRn hIgG4 Reference Antibody(Rozabio) | Anti-H_FcRn IgG4 Antibody(Rozanolixizumab) | Anti-Mouse CD1632 mIgG2b Antibody(2.4G2) |
| ADCCP | ||
| ADCC FcγRIIIa(158F) Jurkat Effector Cell Line | ADCC FcγRIIIa(158V) DDX35TM Jurkat Effector Cell Line | ADCC FcγRIIIa(158V) Jurkat Effector Cell Line |
| ADCC M_FcγRIV Jurkat Effector Cell Line | ADCP FcγRI Jurkat Effector Cell Line | ADCP FcγRIIa DDX35TM Jurkat Effector Cell Line |
| ADCP FcγRIIa R131 Jurkat Effector Cell Line | ADCP FcγRIIb Jurkat Effector Cell Line | |
